five
diseas
acut
respiratori
infect
ari
diarrhea
malaria
measl
aid
respons
half
death
children
younger
age
ari
lead
caus
mortal
children
younger
year
account
nearli
one
fifth
childhood
death
worldwid
kill
million
children
year
ari
often
occur
diseas
includ
measl
malnutrit
aid
childhood
death
attribut
caus
may
actual
caus
ari
largest
portion
ari
death
occur
africa
southeast
asia
worldwid
mortal
caus
ari
children
younger
year
close
link
poverti
croup
bronchiol
pneumonia
three
major
manifest
ari
affect
young
infant
worldwid
virus
belong
paramyxovirida
famili
particularli
respiratori
syncyti
viru
rsv
recent
identifi
human
metapneumoviru
hmpv
human
parainfluenza
virus
hpiv
caus
case
childhood
croup
bronchiol
pneumonia
influenza
viru
also
caus
signific
burden
diseas
young
children
although
signific
children
fulli
recogn
recent
although
influenza
receiv
larg
share
research
focu
fund
alloc
respiratori
virus
pediatr
pathogen
rsv
parainfluenza
lag
far
behind
influenza
effect
vaccin
antivir
drug
although
urgent
need
improv
develop
base
scientif
advanc
past
sever
decad
vaccin
antivir
develop
rsv
parainfluenza
comparison
strikingli
neglect
pediatr
respiratori
diseas
receiv
lowest
level
fund
compar
field
health
research
limit
resourc
devot
rsv
parainfluenza
viru
vaccin
antivir
drug
develop
despit
huge
impact
diseas
ill
hospit
infant
worldwid
therefor
especi
excit
report
import
recent
develop
result
directli
scientif
advanc
appli
prevent
acut
respiratori
diseas
articl
organ
around
sever
import
individu
pediatr
pathogen
respons
croup
bronchiol
pneumonia
children
pathogen
discuss
studi
sever
decad
includ
respiratori
syncyti
viru
parainfluenza
virus
viral
pathogen
newli
identifi
write
human
metapneumoviru
human
coronaviru
light
escal
rate
emerg
new
infecti
agent
fortun
met
equal
rapid
advanc
molecular
method
surveil
pathogen
discoveri
new
organ
ad
list
near
futur
section
therapi
bronchiol
address
sever
final
common
pathway
result
infect
divers
pathogen
highlight
mechan
may
amen
therapeut
approach
articl
conclud
discuss
overarch
impact
new
diagnost
strategi
rsv
lead
caus
bronchiol
lower
respiratori
tract
infect
young
children
account
hospit
bronchiol
rsv
member
pneumoviru
genu
within
pneumovirina
subfamili
paramyxovirida
famili
negativestrand
rna
virus
rsv
replic
initi
nasopharyng
epithelium
later
spread
lower
respiratori
tract
viral
replic
small
airway
caus
inflamm
slough
necrosi
bronchiolar
epithelium
result
edema
increas
mucou
secret
may
depend
sever
diseas
caus
plug
small
airway
atelectasi
airway
narrow
obstruct
primari
infect
rsv
immunolog
host
tend
sever
whether
usual
occur
immunopatholog
mechan
immunolog
immatur
smaller
vulner
airway
infect
infant
combin
factor
unclear
contribut
viru
underli
genet
predisposit
host
compon
inflammatori
respons
form
complex
pictur
genesi
sever
rsv
diseas
individu
role
remain
delin
sever
abnorm
underli
condit
predispos
sever
form
rsv
diseas
enumer
includ
prematur
preexist
lung
diseas
variou
form
immunodefici
howev
one
must
understand
appar
healthi
infant
children
proceed
initi
infect
sever
lower
respiratori
tract
diseas
wherea
other
experi
rel
mild
selflimit
ill
sever
group
recent
identifi
normal
genet
variat
among
human
major
factor
diseas
sever
specif
allel
interleukin
il
receptor
identifi
associ
sever
diseas
promot
variant
tumor
necrosi
factor
tnfa
gene
probabl
also
influenc
diseas
sever
variat
gene
locu
associ
sever
form
diseas
ampl
evid
also
exist
relationship
locu
gene
diseas
sever
recent
identifi
variant
chemokin
receptor
also
seem
predispos
sever
rsv
bronchiol
correl
establish
specif
allel
gene
surfact
increas
diseas
sever
light
mount
evid
specif
genet
contribut
rsv
diseas
sever
possibl
similar
relat
genet
variat
may
underli
predisposit
asthma
link
respiratori
viru
infect
asthma
understand
mechan
wherebi
gene
alter
influenc
pathogenesi
critic
earli
identif
vulner
individu
could
allow
target
use
prophylact
strategi
protect
genet
risk
current
practic
infant
abnorm
underli
condit
prevent
strategi
could
impact
morbid
mortal
ari
also
incid
reactiv
airway
diseas
immun
respiratori
syncyti
viru
inflammatori
respons
respiratori
syncyti
viru
infect
rsv
primari
infect
confer
perman
immun
repeat
reinfect
rsv
within
year
previou
infect
common
young
children
although
subsequ
infect
usual
milder
suggest
protect
sever
diseas
primari
infect
adult
secretori
neutral
antibodi
serum
antibodi
correl
protect
upper
respiratori
tract
infect
wherea
circul
serum
antibodi
particularli
f
g
glycoprotein
shown
protect
infect
decreas
progress
lower
airway
limit
degre
protect
offer
matern
antibodi
underscor
fact
peak
incid
seriou
rsv
diseas
seen
infant
age
month
matern
antibodi
still
circul
within
infant
rsvinduc
lower
respiratori
tract
diseas
bronchiol
pneumonia
result
balanc
cellular
damag
mediat
viral
pathogen
injuri
caus
immun
respons
host
although
immunolog
immunopathogenesi
rsv
infect
fulli
understood
humor
cellular
compon
immun
system
clearli
contribut
protect
diseas
also
pathogenesi
diseas
mous
model
rsv
diseas
use
dissect
contribut
differ
tcell
subset
rsv
protein
patholog
rsv
infect
shown
differ
diseas
outcom
depend
rsv
protein
use
prime
cellular
respons
exampl
balbc
mice
rsv
surfac
protein
g
prime
eosinophil
inflammatori
respons
mediat
cell
reminisc
respons
seen
formalininactiv
rsv
vaccin
model
although
transfer
cytotox
lymphocyt
ctl
mice
result
acceler
viral
clearanc
immunopatholog
also
enhanc
mice
activ
ctl
indic
ctl
associ
respons
also
contribut
immunopatholog
observ
rsvinfect
mice
recent
studi
shown
pattern
recognit
receptor
tolllik
receptor
particip
innat
immun
respons
rsv
respons
trigger
f
protein
anim
model
cellmedi
immun
children
probabl
contribut
host
defens
rsv
also
caus
much
patholog
process
inappropri
immun
respons
may
drive
pulmonari
inflamm
natur
acquir
infect
regul
respons
lymphocyt
rsv
may
critic
determin
clinic
outcom
rsv
infect
abnorm
tcell
regulatori
mechan
may
relat
hyperact
ige
respons
contribut
enhanc
lung
infiltr
sever
proinflammatori
cytokin
detect
respiratori
secret
rsvinfect
individu
includ
rant
macrophag
inflammatori
protein
alpha
mediat
neutrophil
eosinophil
chemotaxi
cell
type
promot
host
defens
tissu
damag
contribut
cell
rsv
diseas
human
support
find
interferon
gamma
ifng
preval
cytokin
produc
rsvspecif
tcell
presenc
ifng
level
rather
level
cytokin
shown
correl
close
rsv
diseas
sever
role
immunopatholog
rsv
highlight
children
receiv
formalininactiv
rsv
vaccin
develop
enhanc
rsv
diseas
exposur
viru
intens
inflammatori
infiltr
lung
vaccin
children
suggest
immunopatholog
caus
enhanc
diseas
anim
model
use
success
studi
immun
correl
patholog
basi
enhanc
diseas
overexuber
inflammatori
respons
lymphocyt
eosinophil
infiltr
ascrib
imbal
ratio
cell
could
result
poor
preserv
f
formalin
inactiv
result
predomin
g
formalininactiv
vaccin
believ
caus
patholog
polar
immun
respons
pulmonari
eosinophilia
children
subsequ
natur
infect
rsv
cell
play
major
role
immunopathogenesi
vaccineenhanc
rsv
diseas
mark
increas
cytokin
express
reduct
express
occur
mice
immun
formalininactiv
vaccin
indic
swing
toward
genesi
enhanc
inflamm
presenc
correl
eosinophil
infiltr
mous
lung
contrast
prime
live
rsv
result
pattern
cytokin
product
prevent
subsequ
enhanc
diseas
recent
studi
mice
suggest
immun
complex
fix
complement
also
play
key
role
pathogenesi
enhanc
diseas
augment
diseas
mice
mediat
immun
complex
abrog
complement
compon
b
celldefici
mice
bronchoconstrict
compon
enhanc
diseas
seem
mediat
complement
wherea
enhanc
pneumonia
compon
diseas
depend
effect
find
enhanc
understand
protect
immun
destruct
inflamm
suggest
import
element
consid
rsv
vaccin
develop
success
vaccin
must
induc
neutral
antibodi
virusspecif
ctl
elicit
cell
respons
correspond
respons
natur
infect
although
live
attenu
vaccin
clearli
achiev
goal
directli
appropri
sever
popul
therefor
novel
strategi
also
appli
develop
nonrepl
vaccin
prevent
respiratori
syncyti
viru
diseas
activ
immun
rsv
vaccin
develop
hamper
past
decad
complex
factor
describ
earlier
concern
result
histori
earli
formalininactiv
vaccin
trial
limit
support
studi
pediatr
respiratori
virus
vaccin
develop
livecandid
attenu
rsv
vaccin
never
observ
caus
enhanc
rsv
diseas
intranas
vaccin
live
viru
vaccin
elicit
better
mucos
immun
parenter
administ
inactiv
viru
vaccin
therefor
develop
live
attenu
vaccin
popul
includ
infant
prioriti
howev
live
attenu
vaccin
pose
challeng
find
balanc
overattenu
subsequ
induct
ineffici
immunolog
respons
underattenu
may
result
diseas
especi
younger
infant
therefor
hearten
report
recent
advanc
molecular
virolog
allow
live
attenu
vaccin
candid
develop
well
toler
infant
protect
challeng
recoveri
infecti
viru
cdna
clone
rsv
base
advanc
molecular
virolog
last
decad
complet
chang
outlook
develop
live
attenu
rsv
vaccin
new
vaccin
candid
develop
introduc
combin
attenu
mutat
recombin
rsv
direct
manipul
dna
intermedi
new
strategi
also
advantag
pediatr
respiratori
virus
discuss
later
specif
mutat
introduc
base
rational
attenu
effect
strategi
base
understand
genet
basi
attenu
appli
design
vaccin
refer
revers
genet
begin
replac
method
serial
passag
virus
chemic
mutagenesi
strategi
classic
use
gener
attenu
mutat
live
coldpassag
cp
temperaturesensit
ts
rsv
vaccin
cpt
vaccin
contain
mani
attenu
mutat
attract
candid
live
attenu
rsv
vaccin
one
cpt
vaccin
candid
safe
immunogen
rsvseroneg
infant
young
month
suffici
attenu
infant
therefor
addit
attenu
mutat
ad
use
novel
technolog
one
new
vaccin
candid
contain
five
new
independ
attenu
genet
element
karron
colleagu
evalu
recombin
rsv
vaccin
clinic
trial
first
time
candid
vaccin
well
toler
respons
mainli
mild
ill
lower
respiratori
tract
ill
observ
associ
viral
infect
administr
second
dose
vaccin
show
restrict
viral
replic
prove
vaccin
could
induc
protect
immun
consist
mechan
natur
immun
antibodi
respons
live
attenu
viru
primari
mediat
protect
induc
vaccin
thu
seem
first
rsv
vaccin
candid
appropri
attenu
young
infant
includ
infant
month
age
although
half
youngest
infant
show
antibodi
respons
limit
replic
second
dose
suggest
infant
protect
critic
infant
vulner
present
challeng
vaccin
develop
success
trial
provid
map
futur
trial
recombin
vaccin
rsv
pediatr
respiratori
pathogen
subunit
vaccin
viabl
infant
therefor
limit
use
normal
popul
may
provid
suitabl
approach
vaccin
immunosuppress
popul
high
risk
sever
rsv
infect
includ
high
risk
children
elderli
possibl
matern
immun
one
viral
surfac
glycoprotein
fusion
protein
f
use
antigen
develop
subunit
vaccin
purifi
f
protein
pfp
f
subunit
vaccin
shown
moder
immunogen
well
toler
healthi
seroposit
children
older
month
children
older
month
cystic
fibrosi
children
older
month
chronic
lung
diseas
prematur
metaanalysi
studi
suggest
vaccin
reduc
incid
rsv
infect
lower
respiratori
tract
infect
vaccin
may
show
promis
pregnant
women
recent
trial
produc
fourfold
increas
neutral
antibodi
titer
mother
infant
birth
month
age
anoth
subunit
vaccin
candid
peptid
g
receptorbind
glycoprotein
rsv
conjug
albuminbind
domain
streptococc
protein
g
vaccin
well
toler
induc
neutral
antibodi
respons
healthi
young
adult
immunogen
elderli
individu
final
subunit
vaccin
contain
copurifi
f
g
protein
formul
alum
adjuv
investig
howev
like
target
vaccin
elderli
adult
high
risk
sever
rsv
infect
effect
vaccin
rsv
wide
avail
passiv
immunoprophylaxi
rsv
antibodi
prepar
import
protect
children
high
risk
sever
rsv
diseas
human
monoclon
antibodi
palivizumab
direct
rsv
fusion
protein
afford
moder
protect
prematur
infant
high
risk
sever
rsv
diseas
palivizumab
administ
monthli
intramuscular
inject
rsv
season
durat
therapi
indic
prophylaxi
depend
gestat
age
presenc
absenc
chronic
lung
diseas
environment
risk
factor
increas
rsv
risk
anoth
rsvspecif
monoclon
antibodi
deriv
palivizumab
develop
compar
palivizumab
antibodi
greater
find
affin
rsv
f
protein
time
potent
neutral
rsv
vitro
effect
reduc
rsv
titer
cotton
rat
model
prepar
current
phase
trial
children
high
risk
rsv
may
prefer
palivizumab
futur
similar
approach
use
monoclon
antibodi
differ
stage
clinic
develop
role
antivir
treat
rsv
infect
remain
uncertain
although
studi
fail
show
correl
viral
load
diseas
sever
other
suggest
reduc
viral
level
correl
improv
clinic
outcom
find
surpris
consid
signific
role
proinflammatori
respons
play
pathogenesi
viru
ribavirin
current
antivir
agent
avail
treat
children
rsv
lower
respiratori
tract
diseas
although
ribavirin
nucleosid
analog
good
activ
rsv
vitro
clinic
studi
examin
effect
children
conflict
therefor
use
children
remain
highli
controversi
consid
certain
target
popul
sever
new
antivir
strategi
rsv
current
investig
includ
promis
approach
f
protein
fusion
inhibitor
rsv
f
fusion
glycoprotein
like
f
paramyxovirus
mediat
fusion
viral
host
cell
membran
infect
f
protein
form
trimer
synthesi
cleav
transit
cell
surfac
produc
final
membranedist
membraneanchor
subunit
carboxyl
termin
membraneanchor
subunit
paramyxoviru
f
protein
anchor
viral
membran
wherea
newli
expos
amino
termin
contain
fusion
peptid
insert
target
membran
fusion
occur
neutral
ph
initi
paramyxoviru
fusion
peptid
lie
deep
within
hydrophob
core
f
protein
virion
fuse
target
membran
effect
viral
entri
f
protein
must
undergo
activ
step
expos
fusion
peptid
paramyxoviru
author
found
f
protein
activ
adjac
receptorbind
protein
hemagglutininneuraminidas
hn
bind
sialic
acidcontain
receptor
permit
fusion
occur
receptor
bind
receptorbind
protein
trigger
f
fuse
must
interact
respect
receptor
fusion
occur
mechan
shown
true
paramyxovirus
gener
rsv
g
receptor
bind
glycoprotein
must
present
trigger
f
fuse
fig
contain
schemat
structur
transit
occur
f
activ
mediat
membran
merger
ectodomain
membraneanchor
subunit
f
protein
contain
two
hydrophob
domain
fusion
peptid
insert
cellular
target
membran
fusion
transmembranespan
domain
fusion
peptid
adjac
ntermin
heptad
repeat
hrn
transmembran
domain
adjac
ctermin
heptad
repeat
hrc
transient
intermedi
f
anchor
viral
cell
membran
believ
refold
assembl
fusogen
sixhelix
bundl
structur
hrn
hrc
associ
tight
complex
nand
cpeptid
align
antiparallel
arrang
refold
reloc
fusion
peptid
transmembran
anchor
side
pull
viral
cell
membran
close
proxim
drive
fusion
refold
step
f
provid
attract
target
antivir
abil
heptad
repeat
peptid
interfer
analog
fusion
process
hiv
led
clinic
effect
peptid
inhibitor
hiv
infect
enfuvirtid
peptid
deriv
hrcpeptid
region
sever
paramyxovirus
includ
sendai
measl
newcastl
diseas
viru
rsv
interfer
fusion
intermedi
paramyxoviru
f
protein
inhibit
viral
infect
vitro
propos
inhibit
occur
peptid
bind
complementari
heptad
repeat
region
therebi
prevent
hrn
hrc
refold
stabl
structur
requir
fusion
relat
approach
recent
observ
ctermin
hrn
trimer
contain
hydrophob
pocket
provid
potenti
bind
site
small
molecul
might
interfer
stabil
hairpin
structur
could
provid
advantag
use
peptid
clinic
use
low
molecular
weight
molecul
highli
effect
inhibit
rsv
fusion
recent
shown
bind
hydrophob
pocket
hrn
suggest
small
molecul
disrupt
hairpin
derail
rsv
fusion
process
inhibit
ftrigger
process
peptid
small
molecul
interact
heptad
repeat
region
promis
area
develop
antivir
therapi
await
studi
sever
novel
experiment
approach
inhibit
rsv
replic
includ
use
antisens
oligonucleotid
rna
interfer
technolog
approach
although
promis
still
earli
stage
develop
hpiv
type
major
caus
croup
although
rsv
rank
common
agent
bronchiol
pneumonia
hmpv
also
possibl
contribut
significantli
parainfluenza
virus
also
follow
close
behind
alon
respons
approxim
pediatr
respiratori
hospit
unit
state
predomin
caus
croup
young
infant
belong
respiroviru
genu
within
paramyxovirina
subfamili
paramyxovirida
famili
negativestrand
rna
virus
wherea
belong
rubulaviru
genu
although
vaccin
program
antivir
use
help
suppress
caus
respiratori
diseas
children
influenza
measl
children
still
unaid
battl
major
caus
croup
rsv
effect
strategi
prophylaxi
avail
protect
group
risk
weapon
current
avail
parainfluenza
virus
parainfluenza
virus
replic
epithelium
upper
respiratori
tract
spread
lower
respiratori
tract
within
day
croup
result
inflammatori
obstruct
airway
epitheli
cell
small
airway
may
becom
infect
result
necrosi
inflammatori
infiltr
interplay
virusinduc
cell
damag
benefici
immun
respons
inflammatori
respons
contribut
diseas
well
studi
rsv
howev
rsv
diseas
sever
often
probabl
increas
patholog
clinic
diseas
actual
caus
inflammatori
respons
rather
cytopath
effect
viru
fundament
concept
highlight
fact
viru
titer
infect
host
gener
wane
diseas
symptom
becom
appar
viru
titer
correl
sever
lower
respiratori
diseas
patholog
chang
children
die
parainfluenza
infect
suggest
exagger
inflamm
rather
simpli
tissu
destruct
viru
hpiv
primari
infect
confer
perman
immun
howev
although
reinfect
occur
immun
usual
suffici
restrict
viru
replic
lower
respiratori
tract
prevent
sever
diseas
mucos
iga
level
correl
protect
replic
parainfluenza
virus
human
cellmedi
immun
also
contribut
importantli
prevent
diseas
exampl
infect
infant
tcelldefici
caus
fatal
giantcel
pneumonia
hpiv
pneumonia
mortal
bone
marrow
transplant
recipi
cotton
rat
sigmodon
hispidu
model
diseas
use
analyz
factor
affect
pathogenesi
vivo
experiment
infect
cotton
rat
lead
infect
bronchiolar
epitheli
cell
bronchiol
interstiti
pneumonia
mimick
human
diseas
make
relev
model
lower
respiratori
infect
author
studi
cotton
rat
infect
either
wildtyp
variant
virus
contain
hn
molecul
individu
mutat
confer
high
receptorbind
avid
low
neuraminidas
receptorcleav
activ
infect
anim
experienc
normal
clearanc
variant
virus
oppos
wildtyp
virus
howev
hn
protein
alter
led
strike
differ
abil
caus
extens
diseas
cotton
rat
lung
variant
caus
alveol
interstiti
infiltr
wherea
wildtyp
viru
caus
peribronchiol
enhanc
diseas
caus
hn
variant
manifest
greatli
increas
inflammatori
cell
infiltr
alveoli
interstiti
space
lung
find
suggest
differ
variant
caus
modul
inflammatori
respons
differ
hn
protein
activ
variant
dissoci
viral
replic
infect
author
hypothes
mutat
hn
protein
alter
either
affin
receptor
receptorcleav
activ
may
modifi
natur
inflammatori
respons
host
use
hn
variant
dissect
etiolog
enhanc
diseas
may
possibl
identifi
compon
immun
system
respons
contribut
diseas
experi
underway
determin
whether
hn
protein
alter
enhanc
diseas
specif
alter
chemokin
express
result
provid
inform
could
use
develop
therapi
modul
overact
inflammatori
respons
hpiv
infect
develop
vaccin
parainfluenza
virus
hamper
need
induc
immun
respons
young
infant
whose
immatur
immun
system
matern
antibodi
interfer
develop
adequ
immun
respons
inactiv
vaccin
use
infant
late
immunogen
offer
protect
infect
experiment
vaccin
evalu
vaccin
perhap
also
anticip
progress
benefit
greatli
recent
advanc
molecular
virolog
two
differ
strategi
develop
vaccin
one
liveattenu
bovin
parainfluenza
type
vaccin
vaccin
base
coldadapt
attenu
strain
vaccin
attenu
human
natur
host
rang
bovin
viru
use
infect
human
well
toler
induc
similar
level
antibodi
titer
seen
infect
human
viru
therefor
revers
genet
approach
use
gener
set
variant
carri
individu
gene
bovin
viru
chimer
virus
strain
elicit
improv
antibodi
respons
monkey
protect
infect
two
chimer
virus
one
contain
hn
gene
bovin
viru
human
viru
background
contain
f
hn
glycoprotein
gene
human
viru
bovin
viru
background
view
strongest
vaccin
candid
human
trial
latter
candid
combin
host
rang
restrict
major
antigen
determin
permit
effici
replic
vitro
benefici
vaccin
develop
along
host
rang
phenotyp
excel
antigen
bovinehuman
chimer
approach
also
use
creat
strategi
vaccin
simultan
rsv
possibl
also
hmpv
chimer
viru
contain
f
hn
glycoprotein
gene
background
engin
also
express
protect
antigen
rsv
hmpv
strategi
lead
bival
vaccin
use
singl
viru
chimera
also
express
rsv
f
clinic
trial
hpiv
also
theoret
well
suit
vaccin
vector
pediatr
pathogen
vaccin
especi
use
respiratori
portal
entri
intranas
rout
administr
highli
advantag
vaccin
would
immun
within
first
month
life
viru
infect
earli
infanc
wherea
vaccin
use
backbon
could
use
second
half
first
year
life
take
strategi
revers
genet
use
hpiv
backbon
vaccin
one
step
hpiv
could
therebi
use
vaccin
vector
virus
infect
respiratori
portal
includ
sever
acut
respiratori
syndrom
sar
ebola
viru
express
spike
glycoprotein
sarscoronaviru
elicit
neutral
antibodi
respons
protect
challeng
sar
african
green
monkey
express
glycoprotein
ebola
highli
effect
guinea
pig
model
evalu
primat
type
vaccin
could
develop
protect
children
emerg
infect
second
attenu
viru
develop
vaccin
base
live
cpt
vaccin
contain
mani
attenu
mutat
vaccin
welltoler
immunogen
children
infant
even
young
month
evalu
clinic
trial
given
promis
candid
attenu
rsv
vaccin
cpt
vaccin
test
combin
vaccin
although
interfer
occur
two
viru
vaccin
result
justifi
evalu
combin
vaccin
sever
featur
viral
lifecycl
make
parainfluenza
virus
vulner
attack
fig
parainfluenza
virus
enter
target
cell
bind
receptor
molecul
fuse
viral
envelop
cell
membran
gain
access
cytoplasm
bind
fusion
critic
step
infect
proceed
interf
critic
process
entri
stage
viral
lifecycl
would
prevent
diseas
f
protein
found
fulli
activ
adjac
receptorbind
protein
hn
bind
sialic
acidcontain
receptor
permit
fusion
occur
receptor
bind
hn
activ
trigger
f
fuse
mechan
true
paramyxovirus
receptorbind
protein
virus
includ
rsv
measl
viru
hendra
viru
nipah
viru
must
interact
respect
receptor
fusion
occur
author
identifi
function
character
specif
receptorinteract
site
hn
molecul
threedimension
crystal
structur
hn
protein
solv
map
function
site
onto
hn
structur
inform
bind
inhibitor
design
specif
fit
bind
pocket
globular
head
hn
fig
addit
interf
receptor
bind
hn
protein
blockad
interfer
ftrigger
function
hn
protein
occur
hn
protein
contact
receptor
ftrigger
function
provid
target
sever
antivir
strategi
first
base
recent
analysi
ftrigger
process
peptid
correspond
hr
domain
f
see
fig
design
prevent
f
protein
reach
fusionact
state
fig
author
perform
comput
model
base
threedimension
structur
relat
parainfluenza
viru
previous
call
simian
viru
f
predict
peptid
activ
test
predict
experiment
strategi
effect
improv
design
antivir
peptid
paramyxovirus
preliminari
studi
author
laboratori
also
suggest
normal
trigger
process
may
subvert
caus
f
protein
becom
activ
reach
target
host
cell
incapacit
f
mediat
viral
entri
author
shown
specif
mutat
stalk
region
hn
affect
hn
abil
trigger
f
protein
specif
featur
globular
head
region
hn
modul
trigger
function
howev
signal
activ
transmit
hn
f
protein
unknown
exampl
hn
receptor
bind
induc
conform
chang
hn
chang
lead
activ
f
detail
understand
pathway
lead
addit
target
interrupt
viral
entri
pathogenesi
probabl
larg
caus
inflammatori
respons
infect
find
specif
alter
hn
protein
correl
enhanc
patholog
hn
may
play
role
elicit
inflammatori
respons
suggest
approach
modul
inflammatori
respons
may
amelior
diseas
fig
final
hn
molecul
addit
bind
receptor
contain
neuraminidas
receptorcleav
activ
cleav
sialic
acid
moieti
cellular
receptor
allow
new
virion
releas
host
cell
surfac
infect
spread
although
neuraminidas
inhibit
unlik
effect
antivir
strategi
parainfluenza
virus
influenza
viru
specif
inhibit
activ
could
prevent
virion
entri
addit
uninfect
cell
fig
sever
potenti
therapeut
target
activ
pursu
hope
open
new
avenu
parainfluenza
infect
interfer
certainli
strategi
protect
treat
children
parainfluenza
viru
infect
urgent
need
hmpv
newli
identifi
respiratori
viru
associ
lower
respiratori
tract
diseas
infant
children
viru
first
report
netherland
investig
identifi
sequenc
viru
perform
randomli
prime
revers
transcriptionpolymeras
chain
reaction
rtpcr
analysi
respiratori
secret
children
lower
respiratori
tract
diseas
hmpv
belong
metapneumoviru
genu
within
pneumovirina
subfamili
paramyxovirida
famili
negativestrand
rna
virus
hmpv
may
account
much
lower
respiratori
diseas
young
children
previous
unknown
origin
signific
portion
upper
respiratori
infect
may
also
caus
wheez
episod
late
winter
spring
less
frequent
croup
pneumonia
although
signific
inform
hmpv
accru
year
sinc
viru
recogn
caus
respiratori
diseas
much
remain
learn
incid
hpmv
specif
popul
basic
virolog
strain
variat
mechan
pathogenesi
immun
littl
known
correl
immun
hmpv
infect
hostpathogen
balanc
lung
diseas
featur
probabl
share
rsv
parainfluenza
infect
induc
serumneutr
antibodi
experiment
infect
anim
protect
reinfect
induc
primari
infect
sever
anim
model
cotton
rat
model
recent
develop
hmpv
similar
featur
cotton
rat
model
cotton
rat
inocul
intranas
hmpv
infect
cotton
rat
lung
exhibit
histopatholog
chang
peribronchi
inflammatori
infiltr
immunohistochem
stain
detect
viru
lumin
surfac
respiratori
epitheli
cell
throughout
respiratori
tract
cotton
rat
mount
neutral
antibodi
respons
hpmv
subsequ
rechalleng
hmpv
anim
exhibit
partial
protect
term
viral
replic
lung
diseas
therefor
cotton
rat
probabl
use
small
anim
model
hmpv
infect
rsv
reflect
diseas
correl
immun
immunopatholog
children
model
facilit
vivo
studi
pathogenesi
lead
develop
vaccin
antivir
candid
hpmv
vaccin
strategi
immedi
benefit
advanc
revers
genet
vaccin
technolog
develop
rsv
allow
recombin
engin
virus
gener
dna
clone
viral
gene
result
live
attenu
viru
vaccin
develop
hpmv
alreadi
progress
recombin
hmpv
strain
gener
repres
rescu
strain
canada
strain
netherland
strain
entir
cdna
sever
chimer
virus
gener
consid
suitabl
vaccin
candid
exampl
hpmv
virus
sever
individu
gene
small
hydrophob
protein
gene
sh
receptorbind
protein
gene
g
gene
open
read
frame
delet
assess
abil
replic
efficaci
intranas
vaccin
african
green
monkey
genedelet
recombin
viru
although
highli
attenu
also
immunogen
protect
monkey
challeng
hmpv
two
virus
gdelet
promis
vaccin
candid
differ
recombin
approach
chimera
gener
replac
nucleoprotein
phosphoprotein
p
open
read
frame
hmpv
correspond
gene
avian
metapneumoviru
subgroup
c
test
african
green
monkey
immun
intranas
intratrach
chimera
compar
wildtyp
hmpv
immunogen
protect
efficaci
p
chimera
although
exhibit
excel
growth
vitro
make
feasibl
vaccin
develop
also
highli
attenu
thu
p
chimera
could
superb
vaccin
candid
combin
good
growth
vitro
attenu
vivo
excel
protect
primat
model
candid
vaccin
probabl
emerg
clinic
trial
fairli
soon
underscor
import
recent
advanc
molecular
virolog
respiratori
virus
acceler
clinic
vaccin
develop
sever
newli
identifi
member
coronaviru
famili
caus
lower
respiratori
diseas
one
sarscoronaviru
etiolog
agent
sar
first
detect
case
sever
atyp
pneumonia
unknown
origin
report
late
diseas
rapidli
spread
countri
sicken
thousand
individu
april
global
medic
scientif
commun
engag
strike
cooper
effort
led
rapid
progress
identifi
sarscoronaviru
diagnos
sever
diseas
outbreak
effect
contain
research
underway
develop
protect
measur
infrequ
fatal
diseas
second
novel
coronaviru
human
coronaviru
less
virul
seem
far
common
frequent
caus
lower
respiratori
tract
diseas
young
children
two
differ
group
identifi
viru
follow
year
quantit
realtim
pcr
use
defin
clinic
spectrum
diseas
analyz
sampl
prospect
studi
lower
respiratori
tract
infect
children
younger
year
found
third
frequent
detect
pathogen
rsv
infect
strongli
associ
croup
rather
bronchiol
suggest
causal
relationship
therefor
probabl
somewhat
less
pathogen
rsv
thu
anoth
signific
caus
respiratori
diseas
children
ad
list
cell
tropism
receptor
use
recent
analyz
receptor
identif
perform
use
new
technolog
pseudotyp
virus
surfac
protein
one
viru
incorpor
membran
anoth
viral
particl
eg
glycoprotein
retroviru
particl
thu
bind
entri
assay
perform
use
wellcharacter
molecularli
malleabl
retroviru
particl
pseudotyp
allow
engin
desir
variant
viral
envelop
protein
studi
provid
report
assay
assess
envelop
protein
abil
mediat
bind
fusion
entri
identifi
receptor
spike
protein
incorpor
membran
retrovir
particl
analyz
cell
tropism
receptor
engag
protein
found
bind
angiotensinconvert
enzym
receptor
sarscoronaviru
use
receptor
infect
target
cell
potent
neutral
activ
direct
protein
detect
sera
individu
age
year
older
suggest
infect
human
commonli
acquir
childhood
fact
sarscoronaviru
use
receptor
differ
greatli
pathogen
infect
children
seem
frequent
event
rais
concern
pathogen
variant
could
evolv
highlight
need
coronaviru
vaccin
develop
investig
antivir
strategi
began
year
new
viral
agent
identifi
sever
exist
antivir
drug
new
synthet
compound
test
preliminarili
inhibitor
sever
potenti
strategi
identifi
studi
includ
hr
peptid
could
interfer
fusion
protein
function
sever
small
interf
rna
identifi
common
theme
strategi
inhibit
divers
array
pediatr
respiratori
virus
eg
use
hr
peptid
interfer
fusion
entri
like
allow
advanc
studi
one
viru
benefit
antivir
strategi
virus
scientif
progress
understand
viral
replic
entri
fusion
respiratori
virus
like
benefit
search
antivir
strategi
newest
member
group
virus
caus
respiratori
diseas
children
two
lead
pediatrician
summar
state
art
bronchiol
treatment
sum
oxygen
vital
import
littl
convinc
evid
therapi
consist
even
occasion
use
unfortun
year
later
statement
larg
still
true
real
advanc
made
pharmacolog
treatment
bronchiol
occurr
wheez
rsvinduc
bronchiol
asthma
coupl
observ
mani
infant
hospit
bronchiol
caus
rsv
respiratori
virus
increas
risk
recurr
wheez
episod
earli
childhood
larg
direct
drug
develop
focu
acut
bronchiol
variou
asthma
therapi
fact
genet
factor
govern
airway
size
control
airway
function
variabl
inflammatori
respons
viral
infect
togeth
environment
exposur
appear
contribut
pattern
diseas
seen
acut
bronchiol
also
predisposit
recurr
wheezingasthma
although
understand
mechan
link
viral
bronchiol
asthma
critic
light
implic
therapi
associ
remain
elus
result
treat
bronchiol
strategi
treat
acut
asthma
episod
yield
consist
benefit
past
decad
corticosteroid
system
inhal
b
agonist
mix
b
agonist
anticholinerg
theophyllin
tri
gener
larg
ineffect
light
patholog
airway
obstruct
associ
bronchiol
desquam
respiratori
epithelium
airway
wall
edema
lack
effect
surpris
acut
revers
airway
obstruct
although
common
children
asthma
constant
find
patient
viral
bronchiol
may
relat
type
immun
respons
gener
infect
advanc
knowledg
immunolog
inflammatori
factor
contribut
diseas
may
suggest
new
approach
treatment
facilit
understand
relationship
viral
bronchiol
recurr
wheez
cysteinyl
leukotrien
concentr
recent
found
elev
upper
lower
respiratori
tract
secret
infant
rsv
bronchiol
leukotrien
play
key
role
airway
obstruct
associ
asthma
mediat
mucos
edema
mucu
hypersecret
recruit
eosinophil
smooth
muscl
contract
bisgaard
colleagu
show
cours
cysteinyl
leukotrien
blocker
montelukast
infant
acut
rsv
bronchiol
reduc
daytim
cough
increas
number
symptomfre
day
although
studi
popul
includ
children
month
age
experienc
firsttim
wheez
detail
analysi
data
suggest
effect
pronounc
younger
subject
observ
correl
well
evid
higher
level
leukotrien
level
infant
younger
month
studi
design
focus
longterm
rather
acut
effect
insuffici
data
support
use
montelukast
treat
milder
form
diseas
reliev
airway
obstruct
acut
set
author
accompani
editori
note
investig
appropri
studi
popul
document
rsv
infect
need
gaug
benefit
therapi
observ
secret
compos
primarili
desquam
epitheli
cell
obstruct
small
airway
children
bronchiol
suggest
use
recombin
human
deoxyribonucleas
treatment
effect
patient
cystic
fibrosi
one
studi
hospit
infant
acut
rsv
bronchiol
chest
radiograph
discharg
show
recombin
human
dnase
treatment
associ
signific
improv
howev
therapi
affect
clinic
featur
respiratori
rate
wheez
retract
similar
smaller
intervent
studi
sever
ill
patient
also
show
therapi
effect
correct
massiv
atelectasi
avoid
need
mechan
ventil
patient
impend
respiratori
failur
leukotrien
studi
need
defin
use
therapi
intervent
one
focu
address
problem
airway
obstruct
decreas
level
surfact
protein
sp
b
report
infant
rsv
bronchiol
mice
surfact
defici
confer
increas
suscept
inflamm
rsv
infect
increas
suscept
also
found
human
identifi
infant
defici
spa
would
risk
sever
rsv
diseas
would
benefici
target
prevent
therapi
therefor
surfact
replac
logic
effect
improv
lung
function
also
potenti
benefit
decreas
inflamm
small
studi
ventil
patient
rsv
bronchiol
patient
experienc
respiratori
failur
treat
two
dose
bovin
surfact
show
improv
static
complianc
indic
decreas
hyperinfl
decreas
airway
resist
compar
untreat
patient
acut
improv
ga
exchang
occur
group
treat
surfact
show
improv
oxygen
ventil
indic
first
hour
mechan
ventil
unfortun
surfact
current
must
deliv
endotrach
intub
therefor
therapi
reserv
children
respiratori
failur
larger
studi
need
assess
effect
surfact
durat
mechan
ventil
viral
clearanc
develop
accur
rapid
diagnost
assay
respiratori
virus
key
two
seemingli
separ
rapidli
converg
arena
diagnosi
becom
increasingli
import
clinic
manag
individu
children
urgent
need
global
public
health
includ
pathogen
surveil
recent
year
signific
progress
made
appli
advanc
molecular
biolog
respiratori
viru
diagnosi
new
strategi
alreadi
clinic
use
practition
guidelin
clear
data
need
regard
situat
specif
kind
assay
may
appropri
transit
technolog
develop
stage
clinic
use
stage
still
flux
howev
one
may
look
forward
situat
public
health
institut
rapidli
respons
pathogen
aris
commun
practition
abl
use
detail
inform
guid
prevent
therapi
masstag
polymeras
chain
reaction
paradigm
new
detect
strategi
earli
recognit
contain
wide
rang
respiratori
pathogen
recent
bries
colleagu
describ
develop
masstag
pcr
differenti
diagnosi
respiratori
diseas
masstag
pcr
multiplex
assay
pathogen
gene
target
code
librari
distinct
mass
tag
microbi
rna
dna
amplifi
multiplex
rtpcr
use
primer
primer
label
differ
molecular
weight
tag
attach
primer
photocleav
link
amplif
mass
tag
releas
amplifi
materi
uv
irradi
ident
tag
determin
mass
spectrometri
ident
organ
determin
presenc
two
specif
tag
one
primer
technolog
success
appli
respiratori
diseas
first
test
case
multiplex
primer
set
design
identifi
respiratori
pathogen
singl
masstag
pcr
reaction
method
found
highli
sensit
specif
diagnos
viral
bacteri
agent
clinic
sampl
test
perform
use
blind
analysi
previous
diagnos
clinic
specimen
bank
sputum
nasal
swab
lung
wash
masstag
pcr
highli
effect
identifi
pathogen
includ
rsv
hmpv
influenza
coronavirussar
includ
studi
technolog
probabl
use
immedi
public
health
set
identifi
outbreak
global
surveil
technolog
becom
streamlin
mass
spectrometri
becom
easili
access
method
great
potenti
individu
patient
manag
diagnos
respiratori
syncyti
viru
paramyxoviru
human
parainfluenza
viru
clinic
set
rsv
hpiv
antigen
rapidli
identifi
individu
patient
use
commerci
avail
rapid
screen
kit
sensit
specif
test
perform
directli
nasopharyng
secret
use
either
fluorescentconjug
antibodi
elisa
monoclon
antibodi
multiplex
quantit
rtpcrenzym
hybrid
assay
identifi
panel
respiratori
virus
differenti
rsv
viral
subtyp
b
hexaplex
assay
prodess
inc
milwauke
wisconsin
multiplex
rtpcr
assay
detect
rsv
b
influenza
viru
type
b
although
sensit
specif
posit
neg
predict
valu
excel
confirm
viral
cultur
either
rapid
tradit
still
import
especi
neg
result
ill
child
pcrbase
technolog
may
provid
use
contribut
diagnosi
subtyp
rsv
futur
assay
kit
antigen
detect
allow
simpl
screen
children
like
use
commonli
futur
therapi
pediatr
respiratori
virus
becom
avail
howev
hope
import
accur
viral
diagnosi
gain
wider
accept
among
practition
especi
influenza
season
prompt
specif
treatment
influenza
effect
shorten
durat
lessen
sever
diseas
children
identif
etiolog
agent
even
specif
therapi
avail
critic
contain
respiratori
viru
outbreak
avoid
transmiss
vulner
individu
although
hmpv
includ
among
respiratori
pathogen
success
identifi
singl
masstag
pcr
describ
earlier
clinic
diagnosi
recent
identifi
pathogen
still
less
develop
rsv
hpiv
howev
molecular
method
develop
recent
hmpv
viru
respiratori
secret
best
identifi
rtpcr
sever
origin
clinic
report
viru
use
rtpcr
assay
use
pcr
primer
hybrid
polymeras
l
gene
use
l
gene
pcr
product
sequenc
identifi
viru
faster
specif
realtim
rtpcr
test
develop
past
year
also
detect
virus
four
known
genet
lineag
hmpv
diagnost
strategi
develop
use
popul
studi
assess
incid
infect
viru
associ
respiratori
diseas
whether
diagnosi
place
practic
whether
identifi
agent
import
public
health
set
unclear
pancoronaviru
rtpcr
assay
recent
develop
use
assess
respiratori
diseas
hospit
children
origin
consensu
rtpcr
assay
design
amplifi
known
coronavirus
unabl
detect
mismatch
primer
sequenc
new
assay
consensu
primer
modifi
base
align
prototyp
sequenc
addit
sarscoronaviru
two
human
coronavirus
known
infect
respiratori
tract
includ
optim
pancoronaviru
rtpcr
assay
addit
identifi
specif
viral
infect
sequenc
analysi
amplifi
gene
segment
show
isol
could
classifi
two
subtyp
correspond
two
prototyp
sequenc
pancoronaviru
assay
test
four
known
human
coronavirus
also
three
anim
coronavirus
felin
infecti
periton
viru
porcin
hemagglutin
encephalomyel
viru
murin
hepat
viru
result
suggest
assay
effici
amplifi
broad
rang
coronavirus
human
anim
pancoronaviru
rtpcr
assay
could
especi
use
abil
identifi
previous
unknown
coronavirus
colleagu
nation
institut
allergi
infecti
diseas
unwav
support
pediatr
respiratori
viru
research
